| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03002103 Details | 2023-04-26 Interventional | 3 | - | Gemcitabine Paclitaxel Breast Neoplasm… Triple Negative… Triple-Negative… | study design reconsideration - | |||
| NCT04902950 Details | 2023-04-25 Interventional | 4 | 9 | Tranexamic Acid Hematoma Abdominoplasty Panniculectomy | Logistics - | |||
| NCT03625687 Details | 2023-04-25 Interventional | 4 | 19 | Antiviral Agent… Sofosbuvir-velp… Hepatitis Hepatitis C Respiratory Ins… Respiratory Fai… | Lack of funding, transitioned to standard of care Study was terminated prior to completion and prior to meeting enrollment goal primarily due to lack of resources (staffing and funding) and transition of HCV-positive to HCV-negative lung transplants to standard of care. Full planned analysis was not completed due to enrollment number, however primary endpoint was assessed for all 16 subjects receiving treatment. | |||
| NCT03149211 Details | 2023-04-25 Interventional | 3 | 0 | UB-421 HIV-1 Infection | project adjustment - | |||
| NCT04775680 Details | 2023-04-24 Interventional | 1/2 | 25 | Antibodies Lymphoma Lymphoma, Non-H… Non Hodgkin Lym… Solid Tumor | The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical
benefit of enrolled subjects was limited and further development of ADG106 was reconsidered. - | |||
| NCT03889756 Details | 2023-04-24 Interventional | 2/3 | 3 | Ketamine Midazolam Depression Depressive Diso… Depressive Diso… Major Depressiv… | No more funding available to continue since we could not recruit throughout the pandemic. The study was only able to enroll 3 participants before the pandemic started and then ran out of funding to finish the trial. Presented are summary data and to avoid revealing any identifying information of participants, data is presented overall where applicable (e.g. baseline characteristics). | |||
| NCT03635996 Details | 2023-04-24 Interventional | 3 | 169 | Etripamil Tachycardia Tachycardia, Su… Tachycardia, Ve… Paroxysmal Supr… | Study was stopped by the Sponsor - | |||
| NCT03068247 Details | 2023-04-24 Interventional | 3 | 0 | Duloxetine Hydr… Depressive Diso… Depressive Diso… Major Depressiv… | Institution was unable to manufacture radiotracer that was central to the protocol. Study
transferred to another institution. - | |||
| NCT01160926 2009-016524-31 Details | 2023-04-24 Interventional | 1 | 31 | Cediranib Rectal Neoplasm… Rectal Cancer | 2 DLTs had been reported from first 4 patients on lowest possible dose cohort. - | |||
| NCT00811122 Details | 2023-04-24 Interventional | 1 | 2 | Corticosterone Alzheimer Disea… Aphasia, Primar… Dementia Frontotemporal … Pick Disease of… Alzheimer's Dis… | A Fluorine-18 labeled version of the radiopharmaceutical (Flutemetamol) became available. This
version is far superior to the Carbon-11 PiB. There is no need to make this compound available
any longer. - | |||
| NCT05431179 Details | 2023-04-21 Interventional | 3 | 0 | Ibrutinib Immune System D… Immunoprolifera… Lymphatic Disea… Lymphoma Lymphoma, B-Cel… Lymphoma, Mantl… Lymphoma, Non-H… Lymphoprolifera… | Due to a strategic reprioritization based on the rapidly changing clinical and commercial
landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors) - | |||
| NCT04424901 Details | 2023-04-21 Interventional | 2 | 41 | Dipyridamole COVID-19 COVID-19 Pneumo… Vascular Compli… | reduction of Hospitalized COVID patients at UConnHealth No data obtained beyond 9 days of enrollment. If discharged from care, phone follow up limited to data provided by subject report, up to day 9. | |||
| NCT04410445 Details | 2023-04-21 Interventional | 3 | 765 | Nivolumab Melanoma Recurrence Melanoma (Skin) Melanoma Stage … Melanoma Stage … | (Sponsor decision) - | |||
| NCT01658826 Details | 2023-04-21 Interventional | 2 | 91 | Pritelivir Valacyclovir Herpes Genitali… Genital Herpes | - - | |||
| NCT05128344 2021-003015-26 Details | 2023-04-20 Interventional | 3 | 0 | Vigabatrin Muscle Cramp Spasm Spasms, Infanti… | Strategic decision - | |||
| NCT04590781 Details | 2023-04-20 Interventional | 1/2 | 4 | Pembrolizumab Carcinoma Carcinoma, Merk… Lung Neoplasms Small Cell Lung… Merkel Cell Car… Small Cell Lung… | The study has been terminated early by the sponsor due to business decision. Study was terminated by the sponsor and only 2 participants each were enrolled in Parts A and C. No participants were enrolled for Part B. Data were not collected for the prespecified analyses of efficacy, pharmacokinetics, and immunogenicity outcome measures. | |||
| NCT01591291 Details | 2023-04-20 Interventional | 2/3 | 0 | Ondansetron Alcoholism | Grant was transferred to University of Maryland and results were reported under NCT02354703. - | |||
| NCT05220748 Details | 2023-04-19 Interventional | 1 | 0 | Pembrolizumab Carcinoma Carcinoma, Squa… Squamous Cell C… Cutaneous Squam… Head and Neck S… | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. - | |||
| NCT04748588 Details | 2023-04-19 Interventional | 4 | 46 | Bamlanivimab Sotrovimab COVID-19 Communicable Di… Cross Infection Infections Covid19 Nosocomial Infe… SARS-CoV2 Infec… | Equipoise requirement no longer met. - | |||
| NCT04735510 Details | 2023-04-19 Interventional | 3 | 0 | Cyclosporine Cyclosporins Ocular Surface … | study redesigned - |